{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:46:30Z","timestamp":1790397990810,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,10,29]],"date-time":"2008-10-29T00:00:00Z","timestamp":1225238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> Four recent cases of transfusion\u2010related transmission of variant Creutzfeldt\u2010Jakob disease (vCJD) highlight the need to develop a highly sensitive and specific screening test to detect infectivity in the blood of asymptomatic infected individuals. Protein misfolding cyclic amplification (PMCA), a method for the amplification of minute amounts of disease\u2010associated abnormal prion protein (PrP<jats:sup>Sc<\/jats:sup>) to readily detectable levels, could be incorporated into such a test provided that a suitable substrate source for routine use in human PMCA reactions can be found.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> With the use of seed sources from individuals with variant and sporadic CJD, the use of human platelets (PLTs) as a PMCA substrate source was evaluated. The effects of seed\/substrate prion protein gene (<jats:italic>PRNP<\/jats:italic>) codon 129 genotype compatibility on amplification efficiency and freeze\u2010thaw on a substrate's ability to support amplification and the degree of amplification achieved by serial PMCA (sPMCA) were investigated.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> Seed\/substrate <jats:italic>PRNP<\/jats:italic> codon 129 compatibility was found to have a major influence on PrP<jats:sup>Sc<\/jats:sup> amplification efficiency. Individual substrates, of the same <jats:italic>PRNP<\/jats:italic> codon 129 genotype, could be pooled and stored frozen for use in subsequent PMCA reactions. A consistent 10\u2010fold increase in PrP<jats:sup>Sc<\/jats:sup> detection sensitivity was achieved after each round of sPMCA, resulting in a 10,000\u2010fold increase in detection sensitivity after four rounds, with no evidence of de novo PrP<jats:sup>Sc<\/jats:sup> production detected in the unseeded PLT substrate.<\/jats:p><jats:p><jats:bold>CONCLUSIONS:<\/jats:bold> Providing issues of seed\/substrate <jats:italic>PRNP<\/jats:italic> codon 129 compatibility are taken into consideration human PLTs are a suitable, readily available, renewable substrate source for use in human PMCA applications.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2008.01954.x","type":"journal-article","created":{"date-parts":[[2009,1,23]],"date-time":"2009-01-23T14:47:49Z","timestamp":1232722069000},"page":"376-384","source":"Crossref","is-referenced-by-count":38,"title":["Human platelets as a substrate source for the in vitro amplification of the abnormal prion protein (PrP<sup>Sc<\/sup>) associated with variant Creutzfeldt\u2010Jakob disease"],"prefix":"10.1111","volume":"49","author":[{"given":"Michael","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander H.","family":"Peden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Yull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Wight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris V.","family":"Prowse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc L.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Ironside","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian R.","family":"MacGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Head","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,1,23]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15486-X"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16811-6"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69835-8"},{"key":"e_1_2_7_5_2","volume-title":"4th case of variant CJD infection associated with blood transfusion (Press Release)","author":"HPA Press Statement","year":"2007"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1051\/vetres:2008009"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.23.13363"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2204"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05411-3"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0041-1132.2003.00586.x"},{"key":"e_1_2_7_11_2","unstructured":"MinorP BrownP.Diagnostic tests for antemortem screening of Creutzfeldt\u2010Jakob disease. In:TurnerML editor. Creutzfeldt\u2010Jakob disease: managing the risk of transmission by blood plasma and tissues. Bethesda (MD): AABB Press Publishers;2006. p.119\u201048."},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03989"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.1999.7720088.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05403-4"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0042-9007.2004.00411.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.18996-0"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409651102"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/35081095"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0404650101"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1286"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129051"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.82786-0"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M603964200"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.2204"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2003.00199.x"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.11.2742"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.07.045"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2006.050788"},{"key":"e_1_2_7_29_2","volume-title":"The National CJD Surveillance Unit Fifteenth Annual Report 2006: Creutzfeldt\u2010Jakob disease surveillance in the UK","author":"The National Creutzfeldt\u2010Jakob Disease Surveillance Unit","year":"2007"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1580"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38804.511644.55"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70413-6"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0702662104"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth1066"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhin.2000.0790"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2008.01954.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2008.01954.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T13:47:52Z","timestamp":1697291272000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2008.01954.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,23]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.1111\/j.1537-2995.2008.01954.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2008.01954.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,23]]}}}